Standard BioTools Inc. Proceeds from Long-term Lines of Credit
Standard BioTools Inc. (LAB) reported Proceeds from Long-term Lines of Credit of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2023-03-14
- Standard BioTools Inc. proceeds from long-term lines of credit for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Standard BioTools Inc. proceeds from long-term lines of credit for fiscal 2021 was $6.84M.
- Standard BioTools Inc. proceeds from long-term lines of credit for fiscal 2020 was $0.00.
- Standard BioTools Inc. proceeds from long-term lines of credit for fiscal 2019 was $0.00.
| Period end | Proceeds from Long-term Lines of Credit 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-14 |
| 2021-12-31 | $6.84M 10-K · filed 2023-03-14 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-08 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-08 |
| 2011-12-31 | $0.00 10-K · filed 2012-03-26 |
| 2010-12-31 | $3.13M 10-K · filed 2012-03-26 |
| 2009-12-31 | $0.00 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |